Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07728487) titled 'Study of AT-587 in Healthy Subjects' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Atea Pharmaceuticals, Inc.

Condition: Hepatitis E

Intervention: Drug: AT-587

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: July 13, 2026

Target Sample Size: 62

Countries of Recruitment: Belgium

To know more, visit https://clinicaltrials.gov/study/NCT07728487

Disclaimer: Curated by HT Syndication....